down arrow

Wakamoto Pharmaceutical Co., Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3991200001
JPY
276.00
1 (0.36%)

Dec 11

TKS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Koa Shoji Holdings Co., Ltd.
Taiko Pharmaceutical Co., Ltd.
Nippon Chemiphar Co., Ltd.
BrightPath Biotherapeutics Co., Ltd.
Wakamoto Pharmaceutical Co., Ltd.
Noile-Immune Biotech, Inc.
Healios KK
Fuso Pharmaceutical Industries Ltd.
RaQualia Pharma, Inc.
SymBio Pharmaceuticals Ltd.
CanBas Co., Ltd.
Why is Wakamoto Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROE of 0.95%
  • The company has been able to generate a Return on Equity (avg) of 0.95% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of -6.53% over the last 5 years
  • INTEREST(HY) At JPY 0.6 MM has Grown at 92.68%
  • PRE-TAX PROFIT(Q) At JPY -117.48 MM has Fallen at -5,458.31%
  • NET PROFIT(Q) At JPY -108.45 MM has Fallen at -759.76%
3
Underperformed the market in the last 1 year
  • The stock has generated a return of 17.45% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 28.54%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Wakamoto Pharmaceutical Co., Ltd. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Wakamoto Pharmaceutical Co., Ltd.
17.45%
0.18
47.45%
Japan Nikkei 225
28.54%
1.11
25.75%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-6.53%
EBIT Growth (5y)
9.03%
EBIT to Interest (avg)
-256.03
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.67
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
161.58%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.35%
ROE (avg)
0.95%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
160
Industry P/E
Price to Book Value
0.91
EV to EBIT
-16.75
EV to EBITDA
-279.26
EV to Capital Employed
0.88
EV to Sales
0.98
PEG Ratio
NA
Dividend Yield
0.17%
ROCE (Latest)
-5.23%
ROE (Latest)
0.57%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company
NET SALES(Q)

Highest at JPY 2,168.55 MM

-27What is not working for the Company
INTEREST(HY)

At JPY 0.6 MM has Grown at 92.68%

PRE-TAX PROFIT(Q)

At JPY -117.48 MM has Fallen at -5,458.31%

NET PROFIT(Q)

At JPY -108.45 MM has Fallen at -759.76%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.61%

CASH AND EQV(HY)

Lowest at JPY 5,357.05 MM

DEBT-EQUITY RATIO (HY)

Highest at -20.16 %

Here's what is working for Wakamoto Pharmaceutical Co., Ltd.
Net Sales
Highest at JPY 2,168.55 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (JPY MM)

Here's what is not working for Wakamoto Pharmaceutical Co., Ltd.
Interest
At JPY 0.6 MM has Grown at 92.68%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Pre-Tax Profit
At JPY -117.48 MM has Fallen at -5,458.31%
over average net sales of the previous four periods of JPY 2.19 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (JPY MM)

Net Profit
At JPY -108.45 MM has Fallen at -759.76%
over average net sales of the previous four periods of JPY 16.44 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (JPY MM)

Inventory Turnover Ratio
Lowest at 1.61% and Fallen
In each half year in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Cash and Eqv
Lowest at JPY 5,357.05 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio
Highest at -20.16 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."